177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. - Wikidata - awgldk - TriplyDB

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

http://www.wikidata.org/entity/Q33429398

about

Prostate Cancer: Epigenetic Alterations, Risk Factors, and Therapy Updates of prostate cancer staging: Prostate-specific membrane antigen Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [68Ga]PSMA I&T and comparison with published data of [68Ga]PSMA HBED-CC.Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride.Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2.Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma.Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer.History and future technical innovation in positron emission tomography.Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.Targeted PET imaging for prostate-specific membrane antigen in prostate cancer.Precision Medicine and PET/Computed Tomography: Challenges and Implementation.Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.Metal-Based PSMA Radioligands.PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.Advances in medical imaging for the diagnosis and management of common genitourinary cancers.Therapy assessment of bone metastatic disease in the era of 223radium.Imaging and dosimetry for radium-223: the potential for personalized treatment.Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer.Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting?Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer.68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Clinical Translation and First In-Human Use of [44Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review.Current status of theranostics in prostate cancer.Re-thinking the role of radiometal isotopes: Towards a future concept for theranostic radiopharmaceuticals.177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment.The synergy between ionizing radiation and immunotherapy in the treatment of prostate cancer.Comparison of standard and delayed imaging to improve the detection rate of [68Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer.PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.

P2860

Q28073470-875B572B-0617-4F61-A26B-A7D1CAFF7529 Q28079444-621E99B4-2FA7-48B0-8E3F-1E7D44E80112 Q31145236-E060FE93-42D4-498C-BDC4-3903631CD28A Q33441176-AB3479C8-816E-4FED-8BF0-7FB735DA70FA Q33581903-ACA8A830-2114-4400-BE2C-5B52FE2E2570 Q33821017-08584F95-94DB-4B09-AA35-0643747E7674 Q35959942-A8D5B46E-BCB6-4F05-8063-3E1A66DA568F Q36128368-7FEDEDD5-56AE-4484-B9A1-0CAF1D952203 Q37390674-68DDA761-C2A5-45C3-9D03-F8F642B010A4 Q37554235-2A34FD25-A2F7-4DDA-977D-2FAAB4FA66EA Q37590988-7ED13033-EE36-4A1C-BA96-973BA0C35135 Q37662701-737DA055-F8D1-4EDA-A554-28BA41F9369E Q37709519-C9854E4C-A5D7-4C27-BCF2-1CD46400D56D Q38720855-0BD82F87-75C3-4223-9261-ABEC42D083E7 Q38731565-5C958CBA-30C6-4291-B19B-3A43E32C6A4F Q38821290-D886E08F-8887-4D81-9ED0-D7B48C83576C Q38838331-554D5366-8A67-4924-B0E0-D5936D04C5E0 Q39013336-061EBB5B-695C-4EEC-904E-693235BDB4C8 Q39183360-B526527E-0689-4B27-A58E-8869AA320C9A Q39198527-0B943F3A-5F6E-492A-904E-71697B2B191E Q39242140-284B5A70-9509-42FB-9EC6-75557B7CD383 Q39307896-9F254B9A-B5C3-4399-B06A-0748B1D19707 Q39342954-3CEF3875-4E28-400A-B10C-7C5180674140 Q39400630-B51191B4-3323-4C48-86C0-8DBEA6F98215 Q39780216-C3E9519B-C4CF-4959-866E-46AB85D45BDB Q40208178-25CEF244-20BA-4C97-A4E1-59BEF4E5BC62 Q41475179-AF150207-DE7B-442B-8072-E72BE4900E7B Q41549549-D376E255-F71A-41B2-BB46-1255B271445D Q41896043-19D0344F-E4BA-404E-8B55-301D1B748450 Q42335930-21CB7D8A-5E25-44AA-BE5C-061F9B76DCCF Q44895959-4B1DBF3A-5924-4E47-9D4B-72D5C3147EDC Q46225464-8D8C9BBB-2B8B-482A-ACCB-B41A090EB6BF Q46729784-B154FB57-B708-4FAD-A5DA-1BA35AE946EA Q47124584-810A6ECF-A9BF-4C77-A19B-51FF0F8B1142 Q47241139-A3EB432F-04F2-4467-B9D4-8657353C83BE Q47588415-E74147BA-5288-494E-8964-788D1A6AA82C Q47679260-33F33B3F-1E36-450C-8D18-4C9F31F687AE Q47876974-D09E8042-9409-4CF8-86E8-47377CB0CAA8 Q48141689-A0E304A2-5E44-4F08-9E8B-7E3D5D0467BA Q48194472-D452E1A9-15FE-499C-B122-680B67E31087

P2860

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.

http://www.wikidata.org/entity/Q33429398

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

177Lu-Labeled Prostate-Specifi ...... e Cancer: Safety and Efficacy.

@ast

177Lu-Labeled Prostate-Specifi ...... e Cancer: Safety and Efficacy.

@en

type

label

177Lu-Labeled Prostate-Specifi ...... e Cancer: Safety and Efficacy.

@ast

177Lu-Labeled Prostate-Specifi ...... e Cancer: Safety and Efficacy.

@en

prefLabel

177Lu-Labeled Prostate-Specifi ...... e Cancer: Safety and Efficacy.

@ast

177Lu-Labeled Prostate-Specifi ...... e Cancer: Safety and Efficacy.

@en

P1433

Q33429398-9E8495DE-72C0-460E-AA63-4CB4CAD09FDF

P1476

Q33429398-30FDDE8F-241F-4304-B39D-FBD980882167

P2093

Q33429398-0F7AC38C-7F23-4C1D-A04E-251FC0AA21C0

Q33429398-2EA3AC9A-C9C3-4B1E-B827-2CDA6BD9423B

Q33429398-2F6C42D5-088B-46FA-B7BA-DC6BA623ADDA

Q33429398-93363EB9-D00A-4927-A881-A8EE2FE28D23

Q33429398-94C9FBD6-3FE1-4E8D-9D83-255C8D3B31BF

Q33429398-9EB2DCE5-1C73-4625-AB63-7CA702C2FBF7

Q33429398-AF210732-4539-458B-8D9E-FF53A7F3A1CC

Q33429398-CB2136EB-04C6-4110-8AB2-E58893F8AEDE

Q33429398-CDE9D29B-C481-4798-A8BE-427DF6977F2C

Q33429398-EBC226D3-F9D3-40B8-AFAF-D343B810A99B

P304

Q33429398-77C61B08-AA7D-4250-BD1C-98D09EBFA373

P31

Q33429398-24F965C1-6216-4551-B25E-E536BA4CDE69

P356

Q33429398-994BB69E-68CD-46B4-98E8-5546E18BC8C1

P407

Q33429398-14AB9A21-5BCE-41AC-BF47-D5732426FAAE

P433

Q33429398-2DFF808D-AE9D-4D89-855A-56282B3AED91

P478

Q33429398-FE454B5D-3D6E-466E-8B73-DD7A646A1A52

P577

Q33429398-10B9ED9E-68CC-4898-A63A-B825B5235A09

P698

Q33429398-4FA3D2F9-E82F-455C-A7A1-89ED1274D4EC

P356

JNUMED.115.168443

P1433

The Journal of Nuclear Medicine

P1476

177Lu-Labeled Prostate-Specifi ...... e Cancer: Safety and Efficacy.

@en

P2093

Aviral Singh

http://www.w3.org/2001/XMLSchema#string

Christiane Schuchardt

http://www.w3.org/2001/XMLSchema#string

Dirk Mueller

http://www.w3.org/2001/XMLSchema#string

Hans-Jürgen Wester

http://www.w3.org/2001/XMLSchema#string

Harshad R Kulkarni

http://www.w3.org/2001/XMLSchema#string

Ingo Klette

http://www.w3.org/2001/XMLSchema#string

Margret Schottelius

http://www.w3.org/2001/XMLSchema#string

Martina Wirtz

http://www.w3.org/2001/XMLSchema#string

Richard P Baum

http://www.w3.org/2001/XMLSchema#string

Stefan Wiessalla

http://www.w3.org/2001/XMLSchema#string

P304

1006-1013

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.115.168443

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26795286

http://www.w3.org/2001/XMLSchema#string